Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/03/2003US6573297 (2-substituted oxyphenyl)alkanamide derivative, hair growth promoter and external composition for skin using the same
06/03/2003US6573296 Therapeutic quassinoid preparations with antineoplastic, antiviral, and herbistatic activity
06/03/2003US6573295 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
06/03/2003US6573294 Method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound
06/03/2003US6573293 Anticancer agents
06/03/2003US6573292 Treatment of Chronic Lymphocytic Leukemia and B- cell and T-cell lymphomas are provided. These methods comprise administering to a patient in need of treatment an effective amount of certain indole and carbazole compounds, such as
06/03/2003US6573290 DFMO and celecoxib in combination for cancer chemoprevention and therapy
06/03/2003US6573288 Compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of
06/03/2003US6573287 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
06/03/2003US6573285 Method for preventing or treating pain by administering an endothelin antagonist
06/03/2003US6573283 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene
06/03/2003US6573282 Peripherally active anti-hyperalgesic opiates
06/03/2003US6573281 Its pharmaceutically acceptable salts for the treatment or prevention of adaptation disorders, bipolar disorders, and dysthymic disorders.
06/03/2003US6573280 Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent
06/03/2003US6573278 Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
06/03/2003US6573277 Metalloproteinase inhibitor
06/03/2003US6573276 Methods of lowering the levels of A beta 40, A beta 42 and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine, or a physiologically acceptable acid addition salt thereof, and methods of treating
06/03/2003US6573273 Urea substituted imidazoquinolines
06/03/2003US6573272 Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment bacterial infections: which inhibit FabI and are useful for the treatment of bacterial infections.
06/03/2003US6573271 Following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome
06/03/2003US6573270 Endothelin receptor antagonists
06/03/2003US6573266 Piperazine derivatives and their use as anti-inflammatory agents
06/03/2003US6573265 Preventing or treating diseases caused by free radicals of the cellular oxygen metabolism, stimulating nerve cell growth, antagonizing glutamate receptors and/or stimulating the growth notably of glutamergic nerve cells; anticarcinogenic agents;
06/03/2003US6573264 Heteroaryl alkyl piperazine derivatives
06/03/2003US6573263 For improving perception, concentration power, learning power and/ or memory power
06/03/2003US6573262 Compounds for treating mammals infected with HIV virus
06/03/2003US6573261 Method for treating or preventing psychosomatic and psychoimmunologic disorders
06/03/2003US6573260 Cycloalkyl-substituted aminomethylpyrrolidine derivatives
06/03/2003US6573258 Photodynamic porphyrin antimicrobial agents
06/03/2003US6573257 Salen-metal complexes having superoxide, catalase and/or peroxidase activity to treat or prevent diseases from cell or tissue damage
06/03/2003US6573256 Administering dihydroxy vitamin D analogs such as 1-alpha,24-dihydroxyvitamin D2, 1-alpha,24-dihydroxyvitamin D4, 1-alpha,25-dihydroxyvitamin D2; treating cancer
06/03/2003US6573255 Vitamin D analogues
06/03/2003US6573253 Methods for the administration of amifostine and related compounds
06/03/2003US6573252 Therapy and prevention of bony disorders; improved gastrointestinal tolerability
06/03/2003US6573251 Biopolymer to prevent degradation
06/03/2003US6573248 Monocyclic L-nucleosides, analogs and uses thereof
06/03/2003US6573247 Prophylaxis or treatment of varicella-zoster virus or cytomegalo virus infections
06/03/2003US6573246 Modified ether glyceroglycolipids
06/03/2003US6573074 Methods for ansamitocin production
06/03/2003US6573073 Oligonucleotide regulatory sequence that increases promoter activity; vectors; gene therapy for cystic fibrosis; cystic fibrosis transmembrane conductance regulator (CFTR)
06/03/2003US6573071 Given amino acid sequence with a modification resulting in a different processing site; use in treating blood disorders
06/03/2003US6573067 Nucleic acid encoding sodium channels in dorsal root ganglia
06/03/2003US6573044 Methods of using chemical libraries to search for new kinase inhibitors
06/03/2003US6572903 Wildlife nutritional supplement
06/03/2003US6572899 Potent combination of nutrients; Acetyl-L-Carnitine; Ginkgo Biloba; Lipoic Acid; Blueberry Extract; Spinach extract; CoEnzyme Q10; Phosphatidylserine; Phosphatidylcholine. Vinpocetine; dementia and Alzheimers disease
06/03/2003US6572898 Electrolyte gels for maintaining hydration and rehydration
06/03/2003US6572897 Insulin sensitivity maintenance and blood sugar level maintenance formulation for the prevention and treatment of diabetes
06/03/2003US6572895 Treatment of congestive heart failure
06/03/2003US6572893 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
06/03/2003US6572891 Sublingual oral dosage form
06/03/2003US6572890 Drug delivery; therapy for psychological disorders
06/03/2003US6572889 Crosslinked polymer of an unsaturated acid
06/03/2003US6572888 Controlled release lipoic acid
06/03/2003US6572885 Inert pharmaceutically acceptable substrates containing an annalgesic with diameter of .1 mm-3 mm, effective blood levels for at least 24 hours
06/03/2003US6572881 Delivery of polynucleotides to cells; polylactam
06/03/2003US6572880 Methods and transdermal compositions for pain relief
06/03/2003US6572879 Formulations for transdermal delivery of pergolide
06/03/2003US6572878 Method and device for treating scars
06/03/2003US6572876 Soy protein, isoflavone and plant sterol coadministered for atherosclerosis prevention
06/03/2003US6572874 Vaginal delivery of bisphosphonates
06/03/2003US6572871 Pain treatment method and apparatus using heating wrap and analgesic cream
06/03/2003US6572867 Reducing plasma levels of anti-( alpha Gal(1,3)Gal) antibodies; nonimmunogenic polymers comprise alpha Gal(1,3) Gal moieties covalently linked to said polymer; cross-links are covalent tethers, derived from N-hydroxysulfosuccinimide
06/03/2003US6572858 Uses for anti-malarial therapeutic agents
06/03/2003US6572852 Genetic engineering
06/03/2003US6572850 Treating obesity by administering a polyether substituted with a pendant B-lactone group;reduction in fat hydrolysis and absorption
06/03/2003US6572848 Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins
06/03/2003US6572841 Composition and method for decreasing upper respiratory airway resistance
06/03/2003US6572839 Sensitizer for tumor treatment
06/03/2003US6572754 Method for producing a tin film on the inner surface of hollow copper alloy components
06/03/2003US6572638 Method of controlling body temperature while inhibiting thermoregulatory responses
06/03/2003CA2413491A1 Treatment for ischemic stroke
06/03/2003CA2354880C Method for the preparation of citalopram
06/03/2003CA2332652C .delta.16 unsaturated c17 heterocyclic steroids useful as steroid c17-20 lyase inhibitors
06/03/2003CA2285914C Process and intermediates for a .beta.3-adrenergic receptor agonist
06/03/2003CA2282757C Opthalmic composition
06/03/2003CA2275554C Intranasal formulations for treating sexual disorders
06/03/2003CA2273446C Piperidones
06/03/2003CA2251912C Inclusion complexes of aryl-heterocyclic salts
06/03/2003CA2223625C Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
06/03/2003CA2116224C Novel alpha-mannosidase inhibitors
06/03/2003CA2115432C Substituted .beta.-amino acid derivatives useful as platelet aggregation inhibitors
06/03/2003CA2108266C Convertible microemulsion formulations
06/03/2003CA2103906C Iloprost with action against cerebral malaria
06/03/2003CA2076424C Phosphoinositol-glycan-peptide with insulin-like action
06/03/2003CA2047858C (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
05/2003
05/30/2003WO2003044209A1 Novel tetronic acid derivative
05/30/2003WO2003044208A1 Novel tetronic acid dervative
05/30/2003WO2003044184A1 Treatment of pml targeting jc virus agno
05/30/2003WO2003044170A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003WO2003044162A2 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003WO2003044144A1 Foamable antimicrobial formulation
05/30/2003WO2003044059A1 Agonists of recombinant human histamine h3 receptor
05/30/2003WO2003044038A2 Biologically active complex
05/30/2003WO2003044033A1 Novel immunosuppressants
05/30/2003WO2003044031A1 Technetium or rhenium complexes, radiopharmaceutical products comprising them
05/30/2003WO2003044024A1 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof
05/30/2003WO2003044023A1 The use of anti-histaminics for acute reduction of elevated intracranial pressure
05/30/2003WO2003044021A2 Substituted indolizine-like compounds and methods of use
05/30/2003WO2003044020A1 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof
05/30/2003WO2003044019A1 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]-nonane derivatives, preparation and therapeutic use thereof
1 ... 5450 5451 5452 5453 5454 5455 5456 5457 5458 5459 5460 5461 5462 5463 5464 5465 5466 5467 5468 5469 5470 ... 7860